Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
format_facet:"Aufsätze"
topic_facet:"Recruitment Status: Authorised-recruitment may be ongoing or finished"
topic_facet:"Medical Condition: Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide MedDRA version: 16.1Level: HLTClassification code 10028229Term: Multiple myelomasSystem Organ Class: 100000004851;Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Patients+with+Relapsed+Refractory+Multiple+Myeloma+who+are+Refractory+to+Lenalidomide+MedDRA+version%3A+16.1Level%3A+HLTClassification+code+10028229Term%3A+Multiple+myelomasSystem+Organ+Class%3A+100000004851%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Patients+with+Relapsed+Refractory+Multiple+Myeloma+who+are+Refractory+to+Lenalidomide+MedDRA+version%3A+16.1Level%3A+HLTClassification+code+10028229Term%3A+Multiple+myelomasSystem+Organ+Class%3A+100000004851%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Patients+with+Relapsed+Refractory+Multiple+Myeloma+who+are+Refractory+to+Lenalidomide+MedDRA+version%3A+16.1Level%3A+HLTClassification+code+10028229Term%3A+Multiple+myelomasSystem+Organ+Class%3A+100000004851%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
PubPharm (20)
1
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide - OCEAN
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
4
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide - OCEAN
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
5
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide - Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethaso
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
6
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide - Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethaso
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
7
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
Multicenter study to compare the combination of Melflufen/Dexamethasone vs. Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/ Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
Multicenter study to compare the combination of Melflufen/Dexamethasone vs. Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma. : A Randomized, Controlled, Open-Label, Phase 3 Study of Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone for Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Medienart: Aufsätze
Filter aufheben
Thema: Recruitment Status: Authorised-recruitment may be ongoing or finished
Filter aufheben
Thema: Medical Condition: Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Lenalidomide MedDRA version: 16.1Level: HLTClassification code 10028229Term: Multiple myelomasSystem Organ Class: 100000004851;Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
Aufsätze
20
E-Artikel
20
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
20
610
Medical Condition: Patients with Relapsed Refra...
20
Phase: Phase 3
Recruitment Status: Authorised-recruitment may ...
20
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
14
2020-
6
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
20
Englisch
Haven't found what you're looking for?
Wird geladen...